Phase 3 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years.
• People diagnosed with hepatocellular carcinoma (a type of liver cancer) according to specific medical guidelines, or confirmed by laboratory tissue or cell testing.
• People who have not previously received cancer treatment for this liver cancer, except those who have had two or fewer TACE procedures (a type of targeted liver treatment).
• People with a good general physical condition, rated 0 or 1 on a standard medical performance scale (meaning fully active or able to carry out light activity).
• People whose liver function falls within a certain acceptable range, classified as Child-Pugh A or B (a measure of how well the liver is working).
• People whose cancer is classified at a specific stage, where the tumour is limited to one side of the liver and involves certain types of blood vessel involvement, but has not spread to the blood vessels on the opposite side of the liver.
• People who have at least one tumour that can be clearly measured on a scan, using a standard medical measurement method.
• People with a certain hepatitis B marker in their blood must have a low level of the hepatitis B virus; people with hepatitis C antibodies must have no detectable hepatitis C virus in their blood.
• People whose organs (such as kidneys, liver, and bone marrow) are functioning adequately, based on blood test results.
• People whose blood pressure is at or below 150/90 mmHg, whether or not they are taking up to three blood pressure medications, with no changes to those medications in the week before starting the trial.
• People whose doctors expect them to live for more than three months.
• People who are not planning to become pregnant.

Who may not be able to join:

• People whose liver cancer is a specific less common type, such as intrahepatic cholangiocarcinoma, sarcomatoid, mixed, or fibrolamellar cell carcinoma.
• People whose liver cancer has spread to other parts of the body outside the liver.
• People whose cancer is spread diffusely throughout the liver, or where the tumour makes up 50% or more of the liver, or where certain major blood vessels are affected on both sides or in specific other locations.
• People for whom TACE procedures or the drug epirubicin are medically unsuitable.
• People with a known allergy to the ingredients in lenvatinib (one of the study drugs).
• People with a known allergy to the ingredients in camrelizumab (another study drug).
• People who currently have or have had another type of cancer.
• People who are pregnant, breastfeeding, or unwilling to use reliable contraception during the trial.
• People with certain significant heart conditions, including moderate-to-severe reduced heart pumping function, poorly controlled irregular heartbeat, or significant blockages or damage to the heart muscle.
• People with problems with blood clotting or a tendency to bleed abnormally.
• People with a history of serious psychiatric disorders or substance misuse.
• People living with HIV.
• People who have had an organ transplant or a stem cell transplant from another person.
• People with a current active infection.
• People who may have difficulty attending appointments regularly or following the trial requirements (confirm with trial site).
• People who have previously been treated with certain immune checkpoint drugs (anti-PD-1, anti-PD-L1, or anti-PD-L2 therapies).
• People who have had an active autoimmune disease requiring ongoing treatment within the past two years.
• People who have taken steroid medications or immune-suppressing drugs within the seven days before starting the trial.
• People with fluid build-up around the lungs or abdomen that is not being controlled medically.
• People with currently active hepatitis B or hepatitis C infection.
• People who have received a live vaccine within the 30 days before starting the trial.

Important: Always verify eligibility with the trial site directly before applying.